11 recruiting, 4 completed, 2 not yet recruiting, 2 terminated. 21 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 21 | Recruiting 11, Completed 4, Not yet recruiting 2, Terminated 2, Unknown 2 |
| Phase 1 | 6 | Recruiting 4, Terminated 1, Unknown 1 |
Follow Locally Advanced: new trials by email Literature Review of Locally Advanced trials Research Report on Locally Advanced
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Becotatug Vedotin + Pucotenlimab+Platinum Induction and Sequential CCRT for Unresectable LA NSCLC Becotatug Vedotin (MRG003)+pucotenlimab+platinum, radiotherapy - Non-Small Cell Carcinoma of Lung, Locally Advanced | Phase 2 | Not yet recruiting | Sun Yat-sen University | 24 | 2026-11-15 | 2026-10-20 |
| Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer Iparomlimab and Tuvonralimab (QL1706), Paclitaxel, Cisplatin - Uterine Cervical Neoplasms, Locally Advanced | Phase 2 | Recruiting | Sun Yat-sen University | 103 | 2026-07-01 | 2026-06-12 |
| CUE-101with Pembrolizumab for Locally Advanced HPV+HNSCCs CUE-101, Pembrolizumab - Head and Neck Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Recruiting | Yale University | 30 | 2026-05-07 | 2026-07-30 |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) AVZO-103, Combination Agent - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 355 | 2025-10-02 | 2026-10-05 |
| Neoadjuvant Nab-Paclitaxel Plus Oxaliplatin, S-1, and Sintilimab in Early-Onset Resectable Gastric Cancer nab-paclitaxel, oxaliplatin, S-1 - Gastric (Cardia, Body) Cancer, Stomach Adenocarcinoma | Phase 2 | Not yet recruiting | zhoujing | 35 | 2025-10-01 | 2025-06-12 |
| Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer Cemiplimab, Fianlimab, Radiotherapy - NSCLC, Locally Advanced | Phase 2 | Recruiting | Montefiore Medical Center | 76 | 2025-08-07 | 2026-04-13 |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) AVZO-1418, Combination Agent 1, Combination Agent 2 - Solid Tumor Cancer, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Avenzo Therapeutics, Inc. | 480 | 2025-06-04 | 2026-10-16 |
| A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer REC-1245 - Unresectable, Locally Advanced | Phase 1 / Phase 2 | Recruiting | Recursion Pharmaceuticals Inc. | 170 | 2024-11-21 | 2026-08-20 |
| Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors Lattice therapy (LRT) - Cancer, Metastatic Cancer | Phase 2 | Recruiting | University of Cincinnati | 37 | 2024-08-02 | 2026-05-04 |
| PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC standard Radiotherapy, Chemotherapy, Immunotherapy - Stage III Non-small Cell Lung Cancer, Locally Advanced | Phase 2 | Recruiting | TheraOp | 110 | 2024-07-01 | 2025-12-17 |
| Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer Serplulimab, Carboplatin, Pemetrexed - Locally Advanced, Non-small Cell Lung Cancer | Phase 2 | Recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 100 | 2023-03-14 | 2024-09-19 |
| SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer Short-course radiotherapy, Penpulimab, CAPEOX - Rectal Cancer, Locally Advanced | Phase 2 | Recruiting | Ruijin Hospital | 55 | 2023-02-06 | 2025-08-28 |
| Induction Chemotherapy Followed by Short Course Radiotherapy in Rectal Cancer Chemotherapy With FOLFIRINOX ( 5 Fluorouracil, Oxaliplatine and Irinotecan), Radiotherapy - Rectal Cancer, Locally Advanced | Phase 2 | Unknown | Salah Azaïz Cancer Institute | 70 | 2020-11-01 | 2023-05-22 |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) rezatapopt, pembrolizumab - Advanced Solid Tumor, Advanced Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | PMV Pharmaceuticals, Inc | 300 | 2020-10-29 | 2026-10-02 |
| Palbociclib With Cetuximab and IMRT for Locally Advanced Squamous Cell Carcinoma Palbociclib, Cetuximab, Intensity Modulated Radiation Therapy - Head and Neck Cancer, Locally Advanced | Phase 1 / Phase 2 | Unknown | Mahidol University | 27 | 2017-07-19 | 2024-03-15 |
| A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer Atezolizumab, Gemcitabine, Cisplatin - Urothelial Carcinoma, Locally Advanced | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 32 | 2017-03-22 | 2026-09-25 |
| Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas Gemcitabine, AMG 479, Placebo - Adenocarcinoma of the Pancreas, Locally Advanced | Phase 2 | Terminated | NantBioScience, Inc. | 10 | 2012-05-31 | 2024-11-08 |
| Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) Modified FOLFOX6, Conatumumab, Ganitumab - Advanced Solid Tumors, Carcinoid | Phase 2 | Completed | Amgen | 12 | 2011-03-03 | 2021-02-21 |
| QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors AMG 479, AMG 655 - Colorectal Cancer, Locally Advanced | Phase 1 / Phase 2 | Terminated | NantCell, Inc. | 89 | 2009-01-16 | 2024-08-20 |
| Cetuximab + Gemox in Biliary Tract Cancer Cetuximab + Gemcitabine + Oxaliplatin - Unresectable, Locally Advanced | Phase 2 | Completed | Association of Research on the Biology of Liver Tumors | 30 | 2006-10-01 | 2010-10-07 |
Showing 20 of 21. Sign in to see all of them.
Neoplasm Metastasis (7) · Carcinoma, Non-Small-Cell Lung (6) · Colorectal Neoplasms (3) · Neoplasms (3) · Breast Neoplasms (2) · Head and Neck Neoplasms (2) · Lung Neoplasms (2) · Lymphoma (2) · Ovarian Neoplasms (2) · Pancreatic Neoplasms (2) · Rectal Neoplasms (2) · Sarcoma (2) · Small Cell Lung Carcinoma (2) · Adenocarcinoma (1) · Biliary Tract Neoplasms (1)
Neoplasms (17) · Neoplasms by Site (15) · Digestive System Diseases (8) · Digestive System Neoplasms (8) · Bronchial Neoplasms (7) · Carcinoma, Bronchogenic (7) · Lung Diseases (7) · Neoplasms by Histologic Type (7) · Neoplastic Processes (7) · Pathologic Processes (7) · Pathological Conditions, Signs and Symptoms (7) · Respiratory Tract Diseases (7) · Respiratory Tract Neoplasms (7) · Thoracic Neoplasms (7) · Gastrointestinal Diseases (6)
Gemcitabine (4) · Oxaliplatin (4) · Radiotherapy (4) · ganitumab (3) · 130-nm albumin-bound paclitaxel (2) · Carboplatin (2) · Cetuximab (2) · Cisplatin (2) · Drug Therapy (2) · Paclitaxel (2) · conatumumab (2) · pembrolizumab (2) · Bevacizumab (1) · Capecitabine (1) · Epirubicin (1)
Avenzo Therapeutics, Inc. (2) · Sun Yat-sen University (2) · Amgen (1) · Association of Research on the Biology of Liver Tumors (1) · Mahidol University (1) · Memorial Sloan Kettering Cancer Center (1) · Montefiore Medical Center (1) · NSABP Foundation Inc (1) · NantBioScience, Inc. (1) · NantCell, Inc. (1) · PMV Pharmaceuticals, Inc (1) · Recursion Pharmaceuticals Inc. (1) · Ruijin Hospital (1) · Salah Azaïz Cancer Institute (1) · Shanghai Pulmonary Hospital, Shanghai, China (1)
United States (11) · China (5) · Germany (3) · Spain (3) · Austria (2) · Poland (2) · South Korea (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Hungary (1)
Amina Mokrani, A/Prof (1) · John Hamm, MD (1) · Marc Fellous, MD (1) · Mouna Ayadi, A/Prof (1) · Nitin Ohri, MD, MS (1) · Norman Wolmark, MD (1) · Nuttapong Ngamphaiboon, MD (1) · Ren Zhao, MD, PHD (1) · Samuel Funt, MD (1) · Sara Pai, MD (1) · Stefan Rieken, Prof. (1) · Ursula Nestle, Prof. (1)
PMID 18650156, PMID 20065174, PMID 21071270, PMID 2702835, PMID 33862000, PMID 37982827, PMID 38071916, PMID 39033189, PMID 40543428, PMID 40932470, PMID 41740031, PMID 41992146